167 related articles for article (PubMed ID: 32667648)
1. Comparison of Driving Times to Opioid Treatment Programs and Pharmacies in the US.
Kleinman RA
JAMA Psychiatry; 2020 Nov; 77(11):1163-1171. PubMed ID: 32667648
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study.
Joudrey PJ; Chadi N; Roy P; Morford KL; Bach P; Kimmel S; Wang EA; Calcaterra SL
Drug Alcohol Depend; 2020 Mar; 211():107968. PubMed ID: 32268248
[TBL] [Abstract][Full Text] [Related]
3. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S.
Wu LT; John WS; Mannelli P; Morse ED; Anderson A; Schwartz RP
Addict Sci Clin Pract; 2023 Aug; 18(1):45. PubMed ID: 37533071
[TBL] [Abstract][Full Text] [Related]
4. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.
Wu LT; Mannelli P; John WS; Anderson A; Schwartz RP
Subst Abuse Treat Prev Policy; 2023 Sep; 18(1):55. PubMed ID: 37697326
[TBL] [Abstract][Full Text] [Related]
5. Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review.
Risby J; Schlesinger E; Geminn W; Cernasev A
Pharmacy (Basel); 2023 Aug; 11(5):. PubMed ID: 37736904
[TBL] [Abstract][Full Text] [Related]
6. Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability.
Brooner RK; Stoller KB; Patel P; Wu LT; Yan H; Kidorf M
Drug Alcohol Depend Rep; 2022 Jun; 3():. PubMed ID: 35757566
[TBL] [Abstract][Full Text] [Related]
7. A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
[TBL] [Abstract][Full Text] [Related]
8. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
9. Opioid treatment program culture and philosophy: Views of OTP staff and state officials on implementing interim methadone treatment.
Burruss-Cousins K; Mitchell SG; Gryczynski J; Whitter M; Fuller D; Ibrahim A; Schwartz RP
J Subst Use Addict Treat; 2024 Feb; 157():209265. PubMed ID: 38103832
[TBL] [Abstract][Full Text] [Related]
10. Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.
Iloglu S; Joudrey PJ; Wang EA; Thornhill TA; Gonsalves G
Drug Alcohol Depend; 2021 Mar; 220():108534. PubMed ID: 33497963
[TBL] [Abstract][Full Text] [Related]
11. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
12. Access to community pharmacies based on drive time and by rurality across the contiguous United States.
Sharareh N; Zheutlin AR; Qato DM; Guadamuz J; Bress A; Vos RO
J Am Pharm Assoc (2003); 2024; 64(2):476-482. PubMed ID: 38215823
[TBL] [Abstract][Full Text] [Related]
13. Disadvantaged groups have greater spatial access to pharmacies in New York state.
Suri A; Quinn J; Balise RR; Feaster DJ; El-Bassel N; Rundle AG
BMC Health Serv Res; 2024 Apr; 24(1):471. PubMed ID: 38622604
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
15. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
[TBL] [Abstract][Full Text] [Related]
16. Typology of laws restricting access to methadone treatment in the United States: A latent class analysis.
Conway A; Krawczyk N; McGaffey F; Doyle S; Baaklini V; Marshall AD; Treloar C; Davis CS; Colledge-Frisby S; Grebely J; Cerdá M
Int J Drug Policy; 2023 Sep; 119():104141. PubMed ID: 37540917
[TBL] [Abstract][Full Text] [Related]
17. Accessibility of Opioid Treatment Programs Based on Conventional vs Perceived Travel Time Measures.
Kim J; Lee J; Thornhill TA; Dennett J; Lu H; Howell B; Grau LE; Fiellin DA; Heimer R; Gonsalves G
JAMA Netw Open; 2024 Feb; 7(2):e240209. PubMed ID: 38376839
[TBL] [Abstract][Full Text] [Related]
18. Mapping pharmacy deserts and determining accessibility to community pharmacy services for elderly enrolled in a State Pharmaceutical Assistance Program.
Pednekar P; Peterson A
PLoS One; 2018; 13(6):e0198173. PubMed ID: 29864159
[TBL] [Abstract][Full Text] [Related]
19. Geographic variation in availability of opioid treatment programs across U.S. communities.
Jehan S; Zahnd WE; Wooten NR; Seay KD
J Addict Dis; 2024; 42(2):136-146. PubMed ID: 36645315
[TBL] [Abstract][Full Text] [Related]
20. Disparities in Access to Opioid Treatment Programs and Office-Based Buprenorphine Treatment Across the Rural-Urban and Area Deprivation Continua: A US Nationwide Small Area Analysis.
Amiri S; McDonell MG; Denney JT; Buchwald D; Amram O
Value Health; 2021 Feb; 24(2):188-195. PubMed ID: 33518025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
